Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Trastuzumab (Herceptin®): Monoclonal Antibody In The Treatment Of HER2/neu-Overexpressing Breast Cancer In The Metastatic And (Neo)adjuvant Situation

N. Ditsch, S. Rückert, Carolin Kümper, M. Lenhard, S. Kahlert, I. Bauerfeind, K. Friese, M. Untch
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Trastuzumab (Herceptin®) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas. After phase I and II trials, several phase III studies of trastuzumab alone or in combination with various chemotherapies were conducted. Patients with HER2/neu overexpression levels of 3+ determined by immunohistochemical assay or gene amplification (fluorescence in situ hybridization) derive most clinical benefit from trastuzumab. Taking into consideration efficacy and side effect profile, the combination of trastuzumab and paclitaxel showed an improvement of all clinical parameters, including overall survival, for the first time in the history of palliative breast cancer therapy. The application of trastuzumab has meanwhile become an established part of systemic therapy of metastastic breast cancer, and excellent data of its application in the adjuvant setting now exist (NSABP-B31, NCCTG-N9831, HERA), with significantly better relapse-free survival in the treatment arms with trastuzumab. Ongoing trials investigate the role of trastuzumab in the neoadjuvant setting. Trastuzumab is generally well tolerated. Cardiotoxicity is the main concern, thus monitoring of cardiac function is recommended.
This paper references
10.1093/JNCI/DJH133
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
M. Pegram (2004)
Antibody dependent cell-mediated cytotoxicity in breast cancer patients in phase III clinical trials of humanized anti-HER-2 antibody
MD Pegram (1997)
10.1200/JCO.2003.02.018
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
10.1200/JCO.2003.12.109
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
B. Leyland-Jones (2003)
erb B2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
A Borg (1994)
10.3816/CBC.2004.N.019
Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
J. O'Shaughnessy (2004)
10.1016/S0959-8049(00)00227-6
Update on raloxifene to prevent endometrial-breast cancer.
S. Goldstein (2000)
Capecitabine in association with epirubicin and docetaxel as first line chemotherapy in advanced breast cancer A dose-finding study
C. Angiolini (2000)
10.1200/JCO.2001.19.18.3808
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
M. Ellis (2001)
10.1200/JCO.1992.10.7.1044
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.
S. Toikkanen (1992)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
Therapeutic advantage of chemotherapy drugs in combination with trastuzumab against human breast cancer cells with Her-2/neu overexpression
G Konecny (1999)
10.1200/JCO.1998.16.8.2659
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
M. Pegram (1998)
Phase II study of trastuzumab plus gemcitabine in chemotherapypretreated patients with metastatic breast cancer
JA O’Shaughnessy (2004)
Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer
M Theodoulou (2004)
10.1159/000055400
First-Line Herceptin® Monotherapy in Metastatic Breast Cancer
C. Vogel (2001)
Results of Two Open-label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER-2 Positive Advanced Breast Cancer
J. Ze-fei (2006)
10.1093/JNCI/95.2.142
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
G. Konecny (2003)
10.1126/SCIENCE.2992089
Amplification of a novel v-erbB-related gene in a human mammary carcinoma.
C. R. King (1985)
Initial report of the SWOG Biological Correlative Study of c-erbB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with tamoxifen (T) alone
PM Ravdin (1998)
10.1016/0304-3835(94)90194-5
ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
A. Borg (1994)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Herceptin (trastuzumab) in cerebrospinal fluid
BC Pestalozzi (2000)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
c - erbB2 - Überex - pression und Herceptin ® in der Therapie des Mam - makarzinoms ; in Untch M , Konecny G , Sittek H ,
G Konecny
10.1200/JCO.2004.22.14_SUPPL.520
Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease.
A. Buzdar (2004)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.1002/cncr.20207
Cardiac profiles of liposomal anthracyclines
M. Theodoulou (2004)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar